Insights into RNA transcriptome profiling of cardiac tissue in obesity and hypertension conditions

Journal of Cellular Physiology

Volumn 230, Issue 5, 2015, Pages 959-968

  de Fátima Costa, Alzenira ^a   Franco, Octávio Luiz ^a,b  

^a UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^b UNIVERSIDADE CATÓLICA DOM BOSCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN RELATED PROTEIN 2-3 COMPLEX; CALCIUM BINDING PROTEIN; CHEMOKINE RECEPTOR; COMPLEMENT FACTOR; COP9 SIGNALOSOME; CXCL14 CHEMOKINE; CXCL2 CHEMOKINE; CYTOCHROME P450; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DNA BINDING PROTEIN; ENDOTHELIN CONVERTING ENZYME; FATTY ACID BINDING PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GALACTOSYLTRANSFERASE; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 6 RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; MYOSIN HEAVY CHAIN; OSTEONECTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); REACTIVE OXYGEN METABOLITE; RNA; TRANSCRIPTION FACTOR GATA 4; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA; TROPOMODULIN; TROPONIN; UNCOUPLING PROTEIN 1;

ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CONGENITAL HEART DISEASE; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HEART ATRIUM; HEART MUSCLE; HEART MUSCLE CELL; HEART VENTRICLE; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; MICROARRAY ANALYSIS; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TRANSCRIPTOMICS; ANIMAL; GENETICS; METABOLISM; PATHOLOGY;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; HYPERTENSION; MYOCARDIUM; MYOCYTES, CARDIAC; OBESITY; RNA;

EID: 84921632886     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24807     Document Type: Review

References (80)

1. Ahuja P, Sdek P, Maclellan WR. 2007. Cardiac myocytes cell cycle control in development disease and regeneration. Physiol Rev 87:521-544.
2. Archacki S, Wang Q. 2004. Expression profiling of cardiovascular disease. Hum Genom 1:355-370.
3. Asakura M, Kitakaze M. 2009. Global gene expression profiling in the failing myocardium. Circ J 73:7-1568.
4. Baandrup JD, Markvardsen LH, Peters CD, Uffe Schou Jensen KJL, Magnusson NE, Ørntoft TF, Kruhøffer M, Simonsen U. 2011. Pressure load: The main factor for altered gene expression in right ventricular hypertrophy in chronic hypoxic rats. PLoS ONE 6:e15859.
5. Bagnall RD, Tsoutsman T, Shephard RE, Ritchie W, Semsarian C. 2012. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS ONE 7:e44744.
6. Barnegas JR. 2005. Epidemiologia de la iipertensión arterial en España. Hipertensión 22:353-362.
7. Barrans JD, Allen PD, Stamatiou D, Dzau VJ, Liew CC. 2002. Global gene expression profiling of end-stage dilated cardiomyopathy using a human cardiovascular-based cDNA microarray. Am J Pathol 160:2035-2043.
8. Benjamin AM, Nichols M, Burke TW, Ginsburg GS, Lucas JE. 2014. Comparing reference-based RNA-Seq mapping methods for non-human primate data. BMC Genomics 15:570.
9. Camm AJ, Kirchhof P, Lip GYH, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. 2010. Guidelines for the management of atrial fibrillation. Eur Heart J 3:2369-2429.
10. Care A, Catalucci D, Felicetti F, Bonci D, Addario A, Gallo P, Bang ML, Segnalini P, Gu Y, Dalton ND, Elia L, Latronico MV, Høydal M, Autore C, Russo MA, Dorn GW 2nd, Ellingsen O, Ruiz-Lozano P, Peterson KL, Croce CM, Peschle C, Condorelli G. 2007. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13:613-618.
11. Chang J, Oikawa S, Ichihara G, Nanpei Y, Hotta Y, Yamada Y, Tada-Oikawa S, Iwahashi H, Kitagawa E, Takeuchi I, Yuda M, Ichihara S. 2012. Altered gene and protein expression in liver of the obese spontaneously hypertensive/NDmcr-cp rat. Nut Met 9:87.
12. Chen G, Wang C, Shi TL. 2011. Overview of available methods for diverse RNA-Seq data analyses. Sci China Life Sci. 54:1121-1128.
13. Chien KR, Knowlton KU, Zhu H, Chien S. 1991. Regulation of cardiac gene expression during myocardial growth and hypertrophy: Molecular studies of an adaptive physiologic response. Faseb J 5:3037-3046.
14. Colombo PC, Ganda A, Lin J, Onat D, Harxhi A, Iyasere JE, Uriel N, Cotter G. 2012. Inflammatory activation: Cardiac, renal, and cardio-renal interactions in patients with the cardiorenal syndrome. Heart Fail Rev 17:177-190.
15. Corsten MF, Dennert R, Jochems S, Kuznetsova T, Devaux Y, Hofstra L, Wagner DR, Staessen JA, Heymans S, Schroen B. 2010. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease. Circ Cardiovasc Genet 3:499-506.
16. Couderc P, Pathak A, Smih F, Dambrin C, Harmancey R, Buys S, Galinier M, Massabuau P, Roncalli J, Senard JM, Rouet P. 2004. Uncomplicated human obesity is associated with a specific cardiac transcriptome: Involvement of the Wnt pathway. FASEB J. 18:1539-1540.
17. Couderc P, Smih F, Pelat M, Vidal C, Verwaerde P, Pathak A, Buys S, Galinier M, Senard JM, Rouet P. 2003. Cardiac transcriptome analysis in obesity-related hypertension. Hypertension 41:414-421.
18. Divakaran V, Mann DL. 2008. The emerging role of microRNAs in cardiac remodeling and heart failure. Circ Res 103:1072-1083.
19. Dixon JA, Spinale FG. 2009. Large animal models of heart failure. A critical link in the translation of basic science to clinical practice. Circ Heart Fail 2:262-271.
20. Duisters RF, Tijsen AJ, Schroen B, Leenders JJ, Lentink V, van der Made I, Herias V, van Leeuwen RE, Schellings MW, Barenbrug P, Maessen JG, Heymans S, Pinto YM, Creemers EE. 2009. MiR-133 and miR-30 regulate connective tissue growth factor implications for a role of microRNAs in myocardial matrix remodeling. Circ Res 104:170-178.
21. Dumitrascu R, Heitmann J, Seeger W, Weissmann N, Schulz R. 2013. Obstructive sleep apnea. Oxidative stress and cardiovascular disease: Lessons from animal studies. Oxid Med Cell Longev 2013:234631.
22. Essop MF. 2007. Cardiac metabolic adaptations in response to chronic hypoxia. J Physiol 584:715-726.
23. Gora M, Kiliszek M, Burzynska B. 2013. Will global transcriptome analysis allow the detection of novel prognostic markers in coronary artery disease and heart failure? Cur Genom 14:388-396.
24. Gielen S, Schuler G, Adams V. 2010. Cardiovascular effects of exercise training: Molecular mechanisms. Circulation 122:1221-1238.
25. Grzeskowiak R, Witt H, Drungowski M, Thermann R, Hennig S, Perrot A, Osterziel KJ, Klingbiel D, Scheid S, Spang R, Lehrach H, Ruiz P. 2003. Expression profiling of human idiopathic dilated cardiomyopathy. Cardiovasc Res 59:400-411.
26. Hsu J, Hanna P, Van Wagner DR, Barnard J, Serre D, Chung MK, Smith JD. 2012. Whole genome expression differences in human left and right atria ascertained by RNA-sequencing. Circ Cardiovasc Genet 5:327-335.
27. Humphries DE, Sirokman G, Bing OH. 1996. Enhanced galactosyltransferase expression in the failing hearts of spontaneously hypertensive rats. Biochem Biophys Res Com 218:320-324.
28. Ikeda S, He A, Kong SW, Lu J, Bejar R, Bodyak N, Lee KH, Ma Q, Kang PM, Golub TR, Pu WT. 2009. MicroRNA-1 negatively regulates expression of the hypertrophy-associated calmodulin and Mef2a genes. Mol Cell Biol 29:2193-2204.
29. Isono T, Matsumoto T, Wada A, Suzaki M, Chano T. 2012. Global transcriptome analysis of a dog Model of congestive heart failure with the human genome as a reference. J Card Fail 18:872-878.
30. Kahr PC, Piccini I, Fabritz L, Greber B, Schöler H, Scheld HH, Hoffmeier A, Brown NA, Kirchhof P. 2011. Systematic analysis of gene expression differences between left and right atria in different mouse strains and in human atrial tissue. PLoS ONE 6:e26389.
31. Kavak E, Ünlü M, Nistér M, Koman A. 2010. Meta-analysis of cancer gene expression signatures reveals new cancer genes, SAGE tags and tumor associated regions of co-regulation. Nuc Ac Res 38:7008-7021.
32. Kittleson MM, Hare JM. 2005. Molecular signature analysis: Using the myocardial transcriptome as a biomarker in cardiovascular disease. Trends Cardiovasc Med 15:130-138.
33. Komuro I, Yazaki Y. 1993. Control of cardiac gene expression by mechanical stress. AnnU Rev Physiol 55:55-75.
34. Konhilas JP, Watson PA, Maass A, Boucek DM, Horn T, Brian L, Stauffer BL, Luckey SW, Rosenberg P, Leinwand LA. 2006. Exercise can prevent and reverse the severity of hypertrophic cardiomyopathy. Circ Res 98:540-548.
35. Kotchen TA. 2010. Obesity-related hypertension: Epidemiology, athophysiology and clinical management. Am J Hypertens 23:1170-1178.
36. LeGrice IJ, Pope AJ, Sands GB, Whalley G, Doughty RN, Smaill BH. 2012. Progression of myocardial remodeling and mechanical dysfunction in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 303:1353-1365.
37. Lee JH, Gao C, Peng G, Greer C, Ren S, Wang Y, Xiao X. 2011. Analysis of transcriptome complexity through RNA sequencing in normal and failing murine hearts. Circ Res 109:1332-1341.
38. Lee EJ, Kamli MR, Pokharel S, Malik A, Tareq KMA, Roouf Bhat A, Park HB, Lee YS, Kim S, Yang B, Chung KY, Choi I. 2013. Expressed sequence tags for bovine muscle satellite cells, myotube formed-cells, adipocyte-like cells. PLoS ONE 8:e79780.
39. Liu N, Bezprozvannaya S, Williams AH, Qi X, Richardson JA, Bassel-Duby R, Olson EN. 2008. MicroRNA-133a regulates cardiomyocyte proliferation and suppresses smooth muscle gene expression in the heart. Genes Dev 22:3242-3254.
40. Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, Xia J. 2012. The Expression Levels of Plasma micoRNAs in Atrial Fibrillation Patients. PLoS ONE 7:e44906.
41. Lupu S, Mitre A, Dobreanu D. 2014. Left atrium function assessment by echocardiography-physiological and clinical implications. Med Ultrason 16:152-159.
42. Mahgerefteh B, Vigue M, Freestone Z, Silver S, Nguyen Q. 2013. New drugs therapies for the treatment of overweight and obesity patients. Am Health Drugs Benef 6:423-430.
43. Malone JH, Oliver B. 2011. Microarrays deep sequencing and the true measure of the transcriptome. BMC Biol 9:34.
44. Márquez-Salom G, Diez J. 2013. PPAR and local renin-angiotensin systems in cardiovascular and metabolic diseases associated with obesity: A unifying hypothesis. Open J Endocr Metab Dis 3:1-10.
45. Matkovich SJ, Hu Y, Dorn GW, II. 2013. Regulation of Cardiac MicroRNAs by Cardiac MicroRNAs. Circ Res 113:62-71.
46. Matkovich SJ, Hu Y, Eschenbacher WH, Dorn LE, Dorn GW, II. 2012. Direct and indirect involvement of microRNA-499 in clinical and experimental cardiomyopathy. Circ Res 111:521-531.
47. Mendizábal Y, Llorens S, Nava E. 2013. Hypertension in metabolic syndrome: Vascular pathophysiology. Int J Hypertens doi.org/10.1155/2013/230868.
48. Montezan AC, Touyz RM. 2012. Molecular mechanisms of hypertension-reactive oxygen species and antioxidants: A basic science update for the clinician. Can J Cardiol 28:288-295.
49. Nadruz W. 2014. Myocardial remodeling in hypertension. J Hum Hypertens 36. doi: 10.1038/jhh.2014.36.
50. Nguyen DM, El-Serag HB. 2010. The epidemiology of obesity. Gastroenterol Clin North Am 39:1-7.
51. Nishi H, Sakaguchi T, Miyagawa S, Yoshikawa Y, Fukushima S, Saito S, Ueno T, Kuratani T, Sawa Y. 2013. Impact of microRNA expression in human atrial tissue in patients with atrial fibrillation undergoing cardiac surgery. PLoS ONE 8:e73397.
52. Vuylsteke M, Peleman JD, van Eijk MJT. 2007. AFLP-based transcript profiling (cDNA-AFLP) for genome-wide expression analysis. Nat Protoc 2:1399-1413.
53. Piazza N, Wessells RJ. 2011. Drosophila models of cardiac disease. Prog Mol Biol Transl Sci 100:155-210.
54. Poland J, Pareek CS, Pierzchala M, Michno J, Szymanska S, Smoczyn R. 2012. Gene expression profiling by cDNA-AFLP and identification of differentially expressed transcripts of bovine pituitary gland in growing bulls of dairy breeds. An Sci Pap and Rep 30:103-119.
55. Puig O, Wang IM, Cheng P, Pris Zhou Roy S, Cully D, Peters M, Benita Y, Thompson J, Cai TQ. 2010. Transcriptome profiling and network analysis of genetically hypertensive mice identifies potential pharmacological targets of hypertension. Physiol Gen 42A:24-32.
56. Raghavachari N. 2013. Microarray technology: Basic methodology and application in clinical research for biomarker discovery in vascular diseases. Methods Mol Biol 1027:47-84.
57. Rao PK, Toyama Y, Chiang HR, Gupta S, Bauer M, Medvid R, Reinhardt F, Liao R, Krieger M, Jaenisch R, Lodish HF, Blelloch R. 2009. Loss of cardiac microRNA mediated regulation leads to dilated cardiomyopathy and heart failure. Circ Res 105:585-594.
58. Roncalli J, Smih F, Desmoulin F, Dumonteil N, Harmancey R, Hennig S, Perez L, Pathak A, Galinier M, Massabuau P, Malet-Martino M, Senard JM, Rouet P. 2007. NMR and cDNA array analysis prior to heart failure reveals an increase of unsaturated lipids, a glutamine/glutamate ratio decrease and a specific transcriptome adaptation in obese rat heart. J Mol Cel Cardiol 42:526-539.
59. Roy B, Larisa Haupt M, Lyn R. 2013. Griffiths. Alternative Splicing (AS) of genes as an approach for generating protein complexity. Cur Gen 14:182-194.
60. Sander V, Suñe G, Jopling C, Morera C, Belmonte JCI. 2013. Isolation and in vitro culture of primary cardiomyocytes from adult zebrafish hearts. Nat Protoc 8:800-809.
61. Schnabel RB, Baccarelli A, Lin H, Ellinor PT, Benjamin EJ. 2012. Next steps in cardiovascular disease genomic. Research sequencing, epigenetics, and transcriptomics. Clin Chem 58:113-126.
62. Sealfon SC, Chu TT. 2011. RNA and DNA microarrays. Methods Mol Biol 671:3-34.
63. Shaper NL, Mann PL, Shaper JH. 1985. Cell surface galactosyltransferase: Immunochemical localization. J Cell Biochem 28:229-239.
64. Song HK, Hong SE, Kim T, Kim DH. 2012. Deep RNA sequencing reveals novel cardiac transcriptomic signatures for physiological and pathological hypertrophy. PLoS ONE 7:e35552.
65. Stanton LW, Garrard LJ, Damm, D, Garrick BL, Lam A, Kapoun AM, Zheng Q, Protter AA, Schreiner GF, White RT. 2000. Altered patterns of gene expression in response to myocardial infarction. Circ Res 86:939-945.
66. Su W, Gao F, Lu J, Wu W, Zhou G, Lu S. 2012. Levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 mRNAs in patients with primary hypertension or hypertension-induced atherosclerosis. J Int Med Res 40:986-994.
67. Tan FL, Moravec CS, Li J, Hansen CA, McCarthy PM, Young JB, Bond M. 2002. The gene expression fingerprint of human heart failure. PNAS 99:11387-11392.
68. Topkara VK, Mann DL. 2011. Role of microRNAs in cardiac remodeling and heart failure. Cardiovasc Drugs Ther 25:171-182.
69. Touyz RM, Briones AM. 2011. Reactive oxygen species and vascular biology: Implications in human hypertension. Hypert Res 34:5-14.
70. van Rooij E, Sutherland LB, Liu N, Williams AH, McAnally J, Gerard RD, Richardson JA, Olson EN. 2006. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Nati Acad Sci USA 103:18255-18260.
71. van Rooij E, Sutherland LB, Thatcher JE, Dimaio JM, Naseem RH, Marshall WS, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN. 2008. Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci USA 105:13027-13032.
72. Vivanco F, López-Bescós L, Tuñónd J, Egido J. 2003. Proteómica y enfermedad cardiovascular. Rev Esp Cardiol 56:289-302.
73. von Hippel P, Benson R. 2013. Obesity and the natural environment across US counties. Am J Pub Health e1-e7.
74. Wang X, Zhu H, Zhang X, Liu Y, Chen J, Medvedovic M, Li H, Weiss MJ, Ren X, Fan GC. 2012. Loss of the miR-144/451 cluster impairs ischaemic preconditioning-mediated cardioprotection by targeting Rac-1. Cardiovasc Res 94:379-390.
75. White CR, Brock TA, Chang LY, Crapo J, Briscoe P, Ku D, Bradley WA, Gianturco SH, Gore J, Freeman II BA, Tarpey MM. 1994. Superoxide and peroxynitrite in atherosclerosis. Proc Natl Acad Sci USA 91:1044-1048.
76. Wittkopper K, Fabritz L, Neef S, Ort KR, Grefe C, Unsöld B, Kirchhof P, Maier LS, Hasenfuss G, Dobrev D, Eschenhagen T, El-Armouche A. 2010. Constitutively active phosphatase inhibitor-1 improves cardiac contractility in young mice but is deleterious after catecholaminergic stress and with aging. J Clin Invest 120:617-626.
77. Wright KJ, Thomas MM, Betik AC, Belke D, Hepple RT. 2014. Exercise training initiated in late middle age attenuates cardiac fibrosis and advanced glycation end-product accumulation in senescent rats. Exp Gerontol 50:9-18.
78. Yang J, Moravec CS, Sussman MA, DiPaola NR, Fu D, Hawthorn L, Mitchell CA, Young JB, Francis GS, McCarthy PM, Bond M. 2000. Decreased SLIM1 expression and increased elsolin expression in failing human hearts measured by high-density oligonucleotide arrays. Circulation 102:3046-3052.
79. Yung CK, Halperin VL, Tomaselli GF, Winslow RL. 2004. Gene expression profiles in end-stage human idiopathic dilated cardiomyopathy: Altered expression of apoptotic and cytoskeletal genes. Genomics 83:28-297.
80. Zhang J, Guy MJ, Norman HS, Chen YC, Xu Q, Dong X, Guner H, Wang S, Kohmoto T, Young KH, Moss RL, Ge Y. 2011. Top-down quantitative proteomics identified phosphorylation of cardiac troponin I as a candidate biomarker for chronic heart failure. Prot Res 10:4054-4065.